Jeeva Clinical Trials Inc.’s Post

Redwood Scientific Enters into Agreement with Jeeva Clinical Trials Inc. to Launch Clinical Effectiveness Study of its TBX-Free Oral Strips for Smoking and E-cigarette Cessation We are excited to collaborate with George Mason University to execute this study here in northern Virginia. https://hubs.la/Q02l6xxk0 "At Redwood Scientific Technologies, Inc. we are committed to developing safe and effective products to help the millions of adults and youths reclaim their lives from the clutches of nicotine addiction and collaborating with this prestigious group will help make this happen," said Jason Cardiff, Redwood's CEO. "Recognizing the crisis at hand, especially with the youth, and the alarming levels of nicotine in vape devices, our goal is to bring this product to market promptly and into the hands of those in need." #Clinicalresearch #InvestigatorInitiatedTrial #Modernclinicaltrial #CTMS #EDC #patientrecruitment #protocol2publication #Biopharma

Just before the new year, the FDA made a huge breakthrough in how we might treat opioid misuse for decades to come. The Administration has just approved the first-ever medical device designed to identify elevated risk factors for developing opioid use disorder.    This groundbreaking approval opens new doors in the fight against substance misuse. The AvertD test uses a swab for consenting patients who have no prior use of orally administered opioids to test for genetic information that could point to risks of OUD. This is a huge step forward in intervention and personalized care and a game-changer in our efforts to combat the opioid crisis, especially among the youth. By addressing these risk factors early on, we're taking a proactive step in the broader conversation around substance misuse. Given the available evidence and the urgent need for medical devices that can make a positive impact on the overdose crisis, the FDA determined that there is a reasonable assurance of AvertD's safety and effectiveness. Here’s to hoping that further innovation in the field of science can lead to similar, safe breakthroughs for managing the substance misuse crisis in the years to come. Check out the press release in the comments below.  #FDAApproval #OpioidCrisis #SubstanceMisuse #HealthcareInnovation

The blog post, Unseen Perils: The Silent Epidemic of Prescription Drug Misuse and Its Alarming Societal Impact explores the widespread issue of prescription drug misuse, highlighting the danger hidden within our own homes. It underscores the need for a multipronged approach including education, regulation, and monitoring, and emphasizes on shifting societal understanding of addiction as a treatable medical condition rather than a moral failing. The blog advocates for comprehensive strategies centered on prevention, treatment, and policy intervention to confront and mitigate this alarming societal problem.

The blog post, Unseen Perils: The Silent Epidemic of Prescription Drug Misuse and Its Alarming Societal Impact explores the widespread issue of prescription drug misuse, highlighting the danger hidden within our own homes. It underscores the need for a multipronged approach including education, regulation, and monitoring, and emphasizes on shifting societal understanding of addiction as a treatable medical condition rather than a moral failing. The blog advocates for comprehensive strategies centered on prevention, treatment, and policy intervention to confront and mitigate this alarming societal problem.

It is again confirmed that strong D2R antagonism is not necessary for antipsychotic effects. German psychiatrist and researcher Hanns Hippius in 1966 was asked to continue the trials of Clozapine on humans. The results confirmed that clozapine although very weak D2 antagonist was an effective antipsychotic with no disabling neurological side-effects. The psychiatric community remained sceptical because the drug lacked motor side-effects. They believed that if there are no Parkinsonian symptoms due to D2R blockade, the drug is not a true antipsychotic. The more pronounced the extrapyramidal symptoms were, the more effective the drug was. Despite this belief, there were many patients with schizophrenia that were placed on clozapine. Finally, after several large trials summarized by Stille and Hippius, clozapine was launched into the market in several European countries and world! 🙂 New revolution with xanomeline -trospium.

https://lnkd.in/diQhY8RQ A new drug approved based on different mechanism of action as compared to existing drugs.

HealthDay reports that an average of “22 US teens die each week from drug overdoses, a death toll driven by the powerful synthetic opioid fentanyl, a new study reports.” Researchers also have identified 19 “hotspot” counties “where fatal ODs are occurring as much as double the national average.” The overdose death rate “for 14- to 18-year-olds now stands at 5.2 deaths per 100,000, researchers report in the New England Journal of Medicine.” The increase of overdose deaths even though the report notes lower rates of drug use amongst teens “is due to fentanyl found in illicit versions of oxycodone, benzodiazepines and other counterfeit prescription pills.” Study co-author and UCLA researcher Joseph Friedman said in a news release that “teenagers are likely to be unaware of just how high-risk experimenting with pills has become, given the recent rise in counterfeit tablets.” Teen overdoses “occurred at double the national average in Arizona, Colorado and Washington state between 2020 and 2022, researchers discovered.” #onepillcankill #fentanyl #education #prevention #safety https://lnkd.in/epPBzywW

The blog post, Unseen Perils: The Silent Epidemic of Prescription Drug Misuse and Its Alarming Societal Impact explores the widespread issue of prescription drug misuse, highlighting the danger hidden within our own homes. It underscores the need for a multipronged approach including education, regulation, and monitoring, and emphasizes on shifting societal understanding of addiction as a treatable medical condition rather than a moral failing. The blog advocates for comprehensive strategies centered on prevention, treatment, and policy intervention to confront and mitigate this alarming societal problem.

What if what we today call “schizophrenia”, we eventually discover to be several disorders with overlapping symptom clusters and different neurobiological mechanisms? The FDA announcement about a new schizophrenia medication may get us one step closer to this future. The most obvious benefit of the new medication, of course, is that it adds a treatment option for people with schizophrenia. This is a clear win for people with treatment-resistant schizophrenia and their loved ones. There is a second, perhaps less obvious, benefit of having multiple treatment options with differing mechanisms of action. Combined with evolving precision diagnostic solutions (eg. MeOmics Precision Medicine Ltd), this sets up the research community to explore the possibility of different subgroups of schizophrenia that respond to different classes of drugs. Ultimately, testing can be developed to identify these subgroups and the most effective medication can be prescribed right away. This is especially important in psychotic disorders as early treatment preserves cognitive function and improves prognosis. The future of schizophrenia treatment lies in the feedback loop between new medications and a deeper understanding of its underlying causes. #precisionmedicine

The CNS field has been very challenging in the last decade, with the ‘One step forward, one step back’ experience in Alzheimer’s with approvals, refusals and approvals but no funding, combined with unprepared health systems. Other areas, and schizophrenia is one, have seen a dearth of innovation despite high unmet need, so it is heartening to see this significant new approval of #Cobenfy (or KarXT) in #schizophrenia with a new MoA, hopefully the first of several steps forward to realising the latent promise in CNS, as outline in our white paper, The Long Road to Success in CNS, here https://lnkd.in/gamddXiF